Revolutionizing HER2 Interpretation: AI Breakthrough Unveiled by Dr. Chaim Linhart (USCAP 2024)

Back

At USCAP 2024, Chaim Linhart, Ibex co-founder and CTO, addressed the complexities of HER2 scoring in breast cancer diagnostics. Highlighting Ibex’s collaboration with AstraZeneca and Daiichi Sankyo, Linhart showcased AI-driven solutions aimed at enhancing accuracy and consistency in HER2 assessment. This initiative promises to redefine HER2 assessment, potentially revolutionizing breast cancer diagnostics.

Back

About IBEX

IBEX is the leader in AI-powered cancer diagnostics in pathology. We empower physicians to provide every patient with an accurate, timely and personalized cancer diagnosis. Our AI platform is deployed worldwide, supporting pathologists and providers with AI-insights that help improve the quality and accuracy of diagnosis, reduce turnaround times and boost productivity.

By providing my details I agree to the IBEX-AI Terms and conditions and Privacy policy. I also agree to receive emails form IBEX-AI and I understand that I may opt out of IBEX-AI subscriptions at any time.

About IBEX

IBEX is the leader in AI-powered cancer diagnostics in pathology. We empower physicians to provide every patient with an accurate, timely and personalized cancer diagnosis. Our AI platform is deployed worldwide, supporting pathologists and providers with AI-insights that help improve the quality and accuracy of diagnosis, reduce turnaround times and boost productivity.

By providing my details I agree to the IBEX-AI Terms and conditions and Privacy policy. I also agree to receive emails form IBEX-AI and I understand that I may opt out of IBEX-AI subscriptions at any time.

How is artificial intelligence rising to the challenge in breast cancer diagnosis?

How ‘game-changing’ AI is helping discover cancer for the first time in UK | ITV News

The AI revolution in cancer diagnostics with Joseph Mossel, CEO of Ibex Medical Analytics